Healthcare, pharma and life sciences leadership jobs

What a free account opens, and what Foresight adds

Reading is free here, and that is not a trial — every one of these 166 briefs opens in full without paying. What a membership buys is the ability to act on them at volume, to reach the ones outside India, and to be found by them while you are working.

Counted against the 166 open healthcare and life sciences mandates on this page — 56 in India, 110 elsewhere. Prices are annual and all-inclusive, with GST already inside the figure shown; quarterly terms exist at a smaller allowance. Nothing on this page is behind any of them.

Why these seats are open

Every mandate here is filed with the reason it exists. It is the most useful column in the corpus and the one no job board carries.

This sector sits close to the platform average on urgency, and the composition is unremarkable except in one respect: when a healthcare seat opens urgently, the cause is disproportionately a quality or regulatory event rather than a commercial one. An inspection outcome, a serious incident, an accreditation at risk, a recall. Those remove leaders quickly and the replacement is assessed almost entirely on whether they have handled the same thing before.

That produces an uncomfortable but genuinely useful fact: a leader who has carried an organisation through a serious quality episode is at their most employable in precisely that market. Candidates routinely treat such an episode as the thing to minimise in their record, when a meaningful subset of these mandates is specifically looking for somebody who has been through one and can describe what changed.

The planned majority move slowly and deliberately, and in this sector that slowness is structural rather than cultural: appointments frequently require clinical stakeholder agreement as well as board approval, and in regulated manufacturing a senior quality or regulatory appointment may need to be notified or accepted by an authority. Being known before the seat opens matters more here than speed once it does, and an agent reading the corpus continuously is how that happens without a CV moving through a small community.

Closing soonest

95 of these mandates carry a published deadline, and 0 of those fall inside the next fortnight. A seat with no date is not less real — a board that has not set one should not have one invented for it.

• Mon, 26 Oct29 daysGroup Chief Financial Officer — Diagnostic-Instruments BusinessGalway, Ireland · Medical Devices · permanent
• Mon, 26 Oct29 daysDirector of Regulatory Affairs — Interim, Medical DevicesDelhi NCR, India · Medical Devices · interim
• Mon, 26 Oct29 daysDirector of Hospital Integration — Interim, Healthcare ServicesPune, India · Healthcare Services · interim
• Mon, 26 Oct29 daysConsumer Route-to-Market Recovery Authority — National PortfolioMexico City, Mexico · Consumer Health and Personal Care · interim
• Mon, 26 Oct29 daysProduct-and-Material Data Recovery LeaderBengaluru, India · Life Sciences Manufacturing Technology · interim
• Mon, 26 Oct29 daysChief Marketing Officer — Connected-Care PlatformSingapore, Singapore · Medical Devices · permanent
• Mon, 26 Oct29 daysPharma Cold-Chain 3PL Quality Leader — Regional Healthcare LogisticsKuala Lumpur, Malaysia · Pharmaceutical 3PL · interim
• Mon, 26 Oct29 daysSurgical Command-Platform Recovery Authority — Tertiary HospitalsMelbourne, Australia · Tertiary Hospital Systems · interim

Counted at the last refresh of this page, which runs hourly. The mandate itself is the authority on whether it is still open.

Where these mandates come from

• Jobs Directly Posted by Firms107
• Direct Mandates of Gladwin International30
• Jobs Posted by NRCs / Boards16
• Jobs Posted by Fellow Members13

Every mandate on this page arrived here deliberately. The largest group was posted directly by the hiring firm; the next largest are Gladwin's own retained and exclusive mandates. A meaningful number come from boards and their quality or clinical governance committees — a route that barely exists in other sectors — and a smaller number from members hiring into their own organisations.

What that list does not contain is anything scraped. In this sector that distinction has weight beyond the commercial: an organisation replacing leadership after a serious incident will not advertise, because the advertisement is a disclosure to patients, regulators and staff simultaneously. The mandates that matter most here are structurally unadvertised, and every brief has a named person behind it who can answer the question that decides a healthcare appointment — what happened, and what has changed since.

Your name stays yours

This used to be the last thing on the page. For a sitting finance chief it is the first question, so it has been moved to where it is actually asked.

Registering is free and anonymous to the hiring side. You are not in a database a company can browse, and nothing about you reaches a board until you approve a specific named seat. What goes then is a portfolio written for that board and that mandate — not a CV placed into circulation, which is how a confidential search stops being confidential.

A chief executive who is discovered to be looking has a career problem. A chief financial officer who is discovered to be looking has a governance problem, because the market reads it as a signal about the numbers. That asymmetry is the reason this platform is built the way it is, and the reason the seats worth having are never advertised.

How the Terminal places a healthcare and life sciences leader

Read the reporting lines. There is a clinical chain of command and it is not subordinate to the commercial one.

The reporting lines on these mandates contain phrases that appear nowhere else on this platform: a clinical governance committee, a board quality chair, a chief medical officer named alongside a chief executive. They are not decorative. This is the only sector in the corpus with a genuine second chain of command — a clinical authority that can stop a commercial decision and that does not report to the person who made it.

For a commercial leader crossing in, that is the single most important thing to understand, and almost nothing written for candidates explains it. In most industries a governance function advises and escalates. Here, a medical director or a quality chair can halt a product, close a service line or stop a launch, and the chief executive cannot overrule them — because the licence, and frequently a personal registration, sits with the clinical side. Leaders who arrive treating clinical governance as a stakeholder to be managed rather than an authority to be worked with fail quickly and publicly.

The second feature of this corpus is how evenly it splits across engagement types. Permanent, interim, advisory and consulting are almost exactly equal here — the most balanced distribution of any sector on the platform. That is what a sector in structural change looks like: enough permanent seats to build a career, enough project work to enter without one, and a great deal of advisory demand from businesses working out what they should become.

What every route shares is the order of operations. Nothing about you moves until you say it moves. Whisper reads the corpus against your record and proposes a named seat; you approve or decline it; a portfolio is written for that specific organisation and that specific problem; a curator reads it before it leaves; and Gladwin presents you under your Executive Passport. In a sector where clinical and regulatory communities are small and reputations travel through them, a CV in circulation is discovered quickly.

Devices and services are different industries

Medical devices and healthcare services are the two largest groups here, and they have almost nothing in common.

Medical devices is a regulated manufacturing and intellectual-property business. The economics are driven by development cost, regulatory approval, reimbursement decisions and patent life. The leadership problems are quality systems, regulatory submissions, supply chain under change control, and commercialisation into health systems that buy through committees rather than through clinicians. It looks and behaves more like semiconductor manufacturing with a regulator attached than like a hospital.

Healthcare services is a labour and throughput business. The economics are driven by clinician availability, utilisation, payer mix and length of stay. The leadership problems are recruitment and retention of scarce clinical staff, capacity, quality outcomes and a cost base that is largely people. It looks and behaves more like a hospitality or logistics network with a clinical governance layer than like a manufacturer.

The functional titles are the same and candidates move between them far less successfully than they expect. A supply-chain leader from devices moving into a hospital network finds that the constraint is not the supply chain at all; a services operator moving into devices finds that every process change requires a change-control procedure and a regulatory assessment before it can be implemented. Both are excellent leaders applying instincts formed in a different economy.

The remainder of this corpus — pharmaceutical distribution, revenue-cycle services, digital health, medical technology — sits between them, and the practical advice is the same as in manufacturing: identify which pole your record actually sits nearer and target from there. In this corpus a generalist healthcare record reads as an absence of pattern rather than as range, because the two poles are genuinely that far apart.

Working alongside clinical authority, without pretending to have it

The most common failure among commercial leaders in healthcare is not a lack of respect for clinicians. It is the opposite — an attempt to acquire clinical credibility they do not have, which is transparent immediately and costs more standing than simply not having it would.

The leaders who work well with clinical authority do something specific and learnable: they are unambiguous about which decisions are theirs and which are not, and they make the clinical ones easier rather than trying to influence them. A chief operating officer who arrives saying "the clinical judgement is not mine, and my job is to make sure you have what you need to exercise it" is in a stronger position in month one than one who has read the literature and wants to discuss it.

The second thing they do is treat quality data as their own responsibility rather than as clinical reporting. In services businesses, outcome and safety data is frequently owned by the clinical side and reported to the board through it, which leaves the commercial leadership dependent on being told. Leaders who build their own visibility into quality — not to second-guess clinical judgement but to know what is happening — are the ones who are not surprised, and being surprised by a quality failure is the fastest way out of a healthcare chair.

The third is understanding what the second chain of command means for their own accountability. A commercial leader in healthcare cannot delegate a quality outcome to the clinical governance structure and treat it as covered. Boards, regulators and in several jurisdictions the law hold operational leadership accountable for the conditions in which care is delivered — staffing, equipment, workload, escalation — even where the clinical decision itself was somebody else's. That distinction is the whole of the job and it is worth being clear about before accepting one.

Switzerland, Ireland, Kenya, India — an unusually revealing map

The geography of this corpus tells you which parts of the sector are hiring.

Switzerland and Ireland together carry nearly as many mandates as the United States, which is enormously out of proportion to their populations and tells you exactly what is being hired: regulated pharmaceutical and device manufacturing, and the intellectual property and transfer-pricing structures that sit around it. Seats there are technical, heavily regulated, and frequently carry a global scope from a small local base. A leader who has never operated under change control or a quality management system will find the constraint unfamiliar and absolute.

India is the largest single concentration and spans the widest range — hospital networks, devices manufacturing, pharmaceutical distribution, revenue-cycle services and a substantial digital-health sector. The defining constraint across most of it is clinical labour: the model usually works and the question is whether it can be staffed and held to a quality bar at scale. Candidates from capital-intensive healthcare are consistently surprised by how much of the job is workforce.

Kenya appearing in this corpus at a level comparable to Germany and the United Kingdom is worth noticing. It reflects health-services build-out across East Africa, frequently with development-finance or impact-capital involvement, and those mandates have a distinctive character: a genuine double bottom line, funders who ask different questions from commercial investors, and operating conditions that reward improvisation more than optimisation.

In the United States the dominant flavour is payer complexity, and it is the least transferable skill in this sector. Reimbursement, coding, payer contracting and revenue-cycle economics are a specialism with essentially no equivalent elsewhere, and an international candidate should expect the process to test it directly rather than to treat healthcare experience as fungible.

Where these mandates are

• India56
• Switzerland19
• United States15
• Singapore10
• Ireland8
• Kenya7
• Germany7
• United Kingdom6
• Australia6
• Canada4
• Netherlands4
• Denmark4

Counted from open mandates on 27 September 2026. 56 sit in India and 110 elsewhere; markets beyond the top 12 carry the remainder.

Who you would report to

The most revealing line on a brief, and the one candidates most often skip. 119 distinct reporting lines appear across these mandates.

• Group Chief Executive or designated executive-committee sponsor30
• Global Managing Partner and regional partner council8
• Group board and Group Chief Executive6
• Group Chief Executive and the relevant board committee6

Lines named on fewer than four mandates are not shown — the tail is long by design, because a real board writes the structure it has rather than choosing from a menu.

Three reporting lines appear in this corpus that appear nowhere else on the platform, and each one tells you what kind of seat you are reading. A line into a clinical governance committee means the role sits inside a services organisation where clinical authority is formally constituted — and that a significant part of your accountability will be for the conditions in which care is delivered rather than for clinical decisions themselves.

A line into a board quality chair means quality is assured independently of operations, which is the mark of a mature organisation and usually of one that has learned something. It also means a serious event will be investigated by people who do not report to you and your handling assessed separately — which candidates from other sectors read as a lack of trust and should read as a feature.

A line naming a chief medical officer alongside a chief executive is the most significant of the three. It means the seat is genuinely dual-reporting into commercial and clinical authority, and that those two will sometimes want different things. The assessment for such a seat is overwhelmingly about how you hold that tension — not about how you resolve it in the commercial direction, which is the answer most commercial candidates instinctively give and the one that ends the conversation.

How much experience these boards ask for

• 22–28 years89
• 18–22 years43
• 28+ years25

A further 9 mandates state the requirement in their own words rather than as a band — “proven controller responsibility”, “VP-level acquisition finance” — and are not bucketed here.

The band sits at twenty-two to twenty-eight years with a moderate tail beyond, slightly lower than the platform average for a regulated sector. Healthcare recruits from adjacent industries more than its reputation suggests — from manufacturing into devices, from services industries into care delivery — which keeps the distribution from concentrating as hard as, say, financial services.

What closes the gap faster than years is regulated-environment experience of any kind. A leader at nineteen years who has operated under a quality management system, carried an inspection or worked alongside a formally constituted governance authority is more appointable here than one at twenty-eight whose record is entirely unregulated commercial. That experience is acquirable deliberately, and crossing into healthcare from another regulated sector is markedly easier than crossing in from an unregulated one.

Four ways into this market, and they are different products

By work mode: 81 hybrid · 74 onsite · 11 remote. At this level the work is a board relationship and an external stakeholder rather than a set of deliverables, which is why genuinely remote seats are the smallest group.

What these seats pay

Healthcare pays unevenly across its two halves and the gap is structural. Devices and pharmaceutical manufacturing — particularly in Switzerland, Ireland and the United States — pay at levels comparable to any regulated industry on this platform. Healthcare services, where the cost base is clinical labour and the payer is frequently a government or an insurer, pays materially less at equivalent scale, and no amount of benchmarking changes that.

The practical implication for a career is that a crossing between the two halves is a financial event as well as a professional one, in both directions, and the direction people usually want to move is the one that pays less. A services leader attracted by the scale and mission of a hospital network should model what that does to a decade of earnings before deciding rather than after.

The Terminal takes pay from the mandates themselves — the ranges boards actually briefed — and prints no median where the sample is too thin, which in a corpus this size and this split is frequently. The more useful analysis here is the market-by-market and half-by-half comparison the Career, Compensation and Global Mobility Strategy runs, because the label "healthcare" covers two pay markets that barely overlap.

Becoming the apex professional in this field

The healthcare ladder is unusual because a parallel clinical ladder runs beside it, and the two meet only at board level. Commercial leaders are trusted with operations long before they are trusted with quality outcomes, and with quality outcomes long before a board will put them in a seat where clinical and commercial judgement have to be held together.

The rungs below are drawn from what these mandates actually demand. The useful question at each step is not "how large was the service or the business" but "what did I change about the conditions in which care was delivered, and did quality hold".

1. 01

   Functional or site leader

   A function, a facility or a plant — its performance, its people and its compliance with the systems it operates under.

   What stops people here — You are assessed on whether the unit performs within a framework somebody else designed, and in this sector the framework is unusually binding. A strong record here evidences execution under constraint, not judgement about the constraint.

   The bridge — Own a change that required a regulatory or clinical governance decision — a process change under change control, a service redesign, a new site qualification. It is the first evidence that you can work with the second chain of command rather than around it.

2. 02

   Operations or commercial leadership

   A network, a portfolio or a market, with a profit and loss and a quality record that are assessed together.

   What stops people here — The common failure is treating quality as clinical reporting rather than as your own visibility. Leaders who depend on being told what the outcome data says are the ones who get surprised, and being surprised by a quality failure is the fastest way out of a healthcare chair.

   The bridge — Build independent visibility into quality and safety data — not to second-guess clinical judgement but to know what is happening. Then carry one serious quality or regulatory episode personally, which is the experience the seats above are actually assessed on.

3. 03

   Regulatory, quality or clinical-adjacent leadership

   The systems that make the business permitted to operate — quality management, regulatory submissions, clinical governance infrastructure.

   What stops people here — These roles are frequently read by commercial boards as technical rather than as leadership, and the leaders in them under-sell themselves accordingly. The record is often stronger than the person presenting it believes.

   The bridge — Attach a commercial outcome to the regulatory work — an approval that opened a market, a quality rebuild that restored a customer, a submission that landed ahead of a competitor. In this corpus that combination is scarce and disproportionately valuable.

4. 04

   Chief executive or chief operating officer

   The commercial result and the conditions in which care or product quality is delivered — held together, with a clinical authority that is not subordinate to you.

   What stops people here — At this level access is the constraint, and the community is small: clinical, regulatory and commercial networks overlap heavily and reputations travel through all three.

   The bridge — This is what the platform is for. Clinical, regulatory and commercial networks here overlap almost completely; named, confidential mandates reach you before the market sees them, and your record travels under a passport rather than through three communities at once.

5. 05

   Board, quality or clinical governance committee

   Assurance that the board's picture of quality and safety is the true one, over a business where the consequence of it not being is measured in harm.

   What stops people here — Independence is the qualification, and healthcare boards need it alongside genuine literacy in a technical and clinical domain — a narrow intersection. Commercial executives frequently have the second and are conflicted on the first within their own sub-sector.

   The bridge — Build the governance record deliberately — quality or clinical governance committee exposure from inside your executive seat, and a first directorship in an adjacent part of the sector. These seats are among the most consequential non-executive roles available anywhere, and boards treat them accordingly.

The healthcare CV, read by a board that is accountable for harm

Every other sector's worst case is financial. This one's is not, and the document should know that.

The commonest failure in a senior healthcare CV is that it is a commercial document in a sector where the worst outcome is not commercial. Growth, market share, cost reduction and margin belong in it, and a record that contains only those is answering half the question a board is asking. The other half is what happened to quality while all of that was going on.

What belongs in the document and usually does not: the quality and regulatory record, stated plainly. An inspection outcome, a recall, a serious incident, an accreditation, a submission that landed or did not. Including the difficult ones is not a risk here in the way candidates assume — this sector has a long institutional memory and a small community, and a record with no difficult episode reads as either short or edited.

The second omission is the relationship with clinical authority, which is the thing that most distinguishes a leader who will succeed here. If you have worked alongside a medical director or a clinical governance committee, say how — specifically what was yours to decide and what was not, and an occasion when that distinction mattered. Commercial leaders almost never write this down, and it is the clearest available signal that they understand the sector rather than merely wanting to enter it.

For devices and pharmaceutical manufacturing specifically, change control is the vocabulary that matters. Evidence of having led a change through a quality management system, of having carried a regulatory submission, or of having operated a supply chain under those constraints is what separates a credible candidate from an excellent industrial leader who will find the environment unrecognisable.

Every mandate here asks three questions before you may apply

A specimen, not a live brief — the real questions describe the organisation's own clinical or regulatory situation and are not published. Every healthcare mandate on the Terminal carries three of them, authored for that seat.

1. 01Describe a serious quality or regulatory episode in an organisation you led — what the investigation found, your own part in the conditions that allowed it, and what changed.200 words
2. 02Describe an occasion when the commercially right decision and the clinically defensible one were not the same, and how you held that.150 words
3. 03How have you built your own visibility into quality and safety data without second-guessing clinical judgement?150 words

This is the filter, and it is the reason the platform is not a job board. A partner reads a considered answer to a real situation rather than a stack of documents, which means a strong candidate with an imperfect CV is read properly — and it means a speculative application costs you something, which is why the corpus stays worth reading.

Devices, services, regulated manufacturing and the quality board seat

Four healthcare seats whose economics and assessments barely overlap.

The label "healthcare experience" covers two industries that are genuinely that far apart. Medical devices behaves like regulated manufacturing with an intellectual-property layer; healthcare services behaves like a clinical labour network. Both advertise for the same functional titles and assess candidates on almost opposite evidence.

The table below reads across the four, using the scope each brief states, the reporting line it files and the thing the assessment actually turns on.

What a membership actually gets you

Open mandates in this market

20 of 166. Title, market and engagement are open to everyone; the brief itself opens with a free account.

• Healthcare Performance Engineering Manager — Workflow Response ReadinessHyderabad, India · Healthcare Workflow Technology Services · permanent
• Regional Vice President, FP&A — Healthcare Technology ServicesBengaluru, India · Healthcare Technology Services · permanent
• Performance Engineering Service Manager — Test Evidence Continuity, InterimHyderabad, India · Retail and Healthcare Engineering Test Services · interim
• Director — CDMO Business Finance and Customer Capacity ReturnsHyderabad, India · Pharmaceutical Contract Programme Finance · permanent
• Senior Financial Controller — Laboratory Services Asset StewardshipBengaluru, India · Life Sciences Laboratory Services · permanent
• Principal Integration Performance Architect — Dependency Capacity and Tail LatencyBengaluru, India · Retail and Healthcare Integration Platforms · permanent
• Technical Steering Adviser — Performance Evidence and Release ConfidenceHyderabad, India · Retail and Healthcare Product Governance · advisory
• Principal Batch Performance Consulting Lead — Processing Window CapacityHyderabad, India · Retail and Healthcare Scheduled Processing · consulting
• Regional Vice President, Finance — Medical Device LifecycleMumbai, India · Medical Devices · permanent
• Interim Regional Finance Head — Diagnostics SeparationMumbai, India · Diagnostics Technology · interim
• Commercial Risk Committee Adviser — Medical Technology IncentivesMumbai, India · Medical Technology Distribution · advisory
• Chief Financial Officer — MedTech Commerce Channel and Service CapitalMumbai, India · Medical Technology Commerce · permanent
• Industrial Acquisition Financial-Evidence Readiness — Consulting LeadBengaluru, India · Industrial and Pharmaceutical Manufacturing · consulting
• Senior Vice President, Genomics Research — Programme BridgeMumbai, India · Genomics and Medical Research · interim
• Healthcare RCM Contract Margin Finance VP — InterimMumbai, India · Healthcare Revenue Cycle Services · interim
• Health and Education Technology Long-Range Planning Design LeadMumbai, India · Health and Education Technology · consulting
• RCM Automation Investment and Benefit Attribution AdviserMumbai, India · Healthcare Revenue Cycle Services · advisory
• Healthcare-Technology Portfolio Economics AdviserChennai, India · Healthcare Technology · advisory
• Medical-Equipment Treasury and Forecast-Risk ConsultantChennai, India · Medical Equipment · consulting
• AMR and Wastewater Surveillance Portfolio AdviserMumbai, India · Public Health Research · advisory

Questions and answers

How many healthcare and life sciences leadership jobs are open right now?

166 medical devices, healthcare services, pharmaceutical and digital-health mandates are open on the India Board Terminal today, across 27 markets, out of 3,088 open mandates in total. The figure is counted from the live corpus rather than written into the page.

What is a clinical governance committee and why does it matter to me?

It is a formally constituted clinical authority that can stop a commercial decision and does not report to the person who made it. This is the only sector on this platform with a genuine second chain of command, and it is the single most important thing a commercial leader crossing in needs to understand.

I am a commercial leader. How do I work with clinical authority?

Be unambiguous about which decisions are yours and which are not, and make the clinical ones easier rather than trying to influence them. The common failure is attempting to acquire clinical credibility you do not have, which is transparent immediately and costs more standing than not having it would.

Can I move between medical devices and healthcare services?

It is a genuine crossing between two industries. Devices is a regulated manufacturing and IP business — development cost, approval, reimbursement, patent life. Services is a clinical labour and throughput business — staffing, utilisation, payer mix. The titles transfer and the instincts do not.

Why do Switzerland and Ireland carry so many of these mandates?

Because together they nearly rival the United States here, which is enormously out of proportion to their populations. It is regulated pharmaceutical and device manufacturing, plus the intellectual property and transfer-pricing structures around it — technical, heavily regulated seats with global scope from a small local base.

I have a serious quality incident in my history. Should I disclose it?

Yes, and it is frequently an asset rather than a liability. When a healthcare seat opens urgently the cause is disproportionately a quality or regulatory event, and the replacement is assessed on whether they have handled the same thing. A record with no difficult episode reads as either short or edited in a sector with a long memory.

Does healthcare pay well?

Unevenly, and structurally so. Devices and pharmaceutical manufacturing — especially in Switzerland, Ireland and the US — pay comparably to any regulated industry here. Healthcare services, where the cost base is clinical labour and the payer is often a government or insurer, pays materially less at equivalent scale.

Why is the engagement split so even here?

Permanent, interim, advisory and consulting are almost exactly equal in this corpus — the most balanced of any sector on the platform. That is what a sector in structural change looks like: enough permanent seats to build a career, enough project work to enter without one, and heavy advisory demand from businesses working out what they should become.

What does US healthcare experience actually transfer?

Less than candidates expect in one direction and more in the other. Reimbursement, coding, payer contracting and revenue-cycle economics are a specialism with essentially no equivalent elsewhere, so an international candidate should expect it tested directly rather than assume healthcare experience is fungible.

Why does Kenya appear in this corpus?

Health-services build-out across East Africa, frequently with development-finance or impact-capital involvement. Those mandates have a distinctive character: a genuine double bottom line, funders who ask different questions from commercial investors, and conditions that reward improvisation more than optimisation.

How many years of experience do these organisations ask for?

Twenty-two to twenty-eight years with a moderate tail, slightly lower than the platform average for a regulated sector — because healthcare recruits from adjacent industries more than its reputation suggests. What closes the gap faster is regulated-environment experience of any kind.

Will my current organisation find out I am looking?

Not through this platform. Your name is not in a database a hiring side can browse, and nothing about you reaches a board until you approve a specific named seat. Clinical, regulatory and commercial communities in this sector overlap heavily and reputations travel through all three, so a CV in circulation is discovered quickly.

How do I get onto a healthcare board or quality committee?

These boards need independence alongside genuine clinical or technical literacy — a narrow intersection. Build quality or clinical governance committee exposure from inside your executive seat and target an adjacent part of the sector. These are among the most consequential non-executive seats available anywhere, and boards treat them accordingly.

Are remote roles available in this sector?

Very few, and the work-mode cut on this page counts them honestly — hybrid and onsite are close to evenly split. Care is delivered in places and products are made in plants, and a quality culture is not assessed from a dashboard.

What happens after I apply?

Every mandate here carries three questions written for that specific organisation, and they must be answered before an application is accepted. One usually asks directly about a serious quality or regulatory episode — which is the filter, and is far better handled in your own words than discovered later.

The same corpus, entered elsewhere

• functionCFO and finance leadership jobs
• functionCTO, CIO and technology leadership jobs
• functionCOO and operations leadership jobs
• functionCEO, managing director and country head jobs
• sectorTechnology leadership jobs — CTO, CIO and engineering chiefs
• sectorBanking and financial services leadership jobs
• sectorInfrastructure, energy and utilities leadership jobs
• sectorManufacturing and industrial leadership jobs
• sectorLogistics, supply chain and mobility leadership jobs
• sectorConsumer, retail and FMCG leadership jobs
• sectorMedia, entertainment and telecom leadership jobs